Morgan Stanley Alkermes Plc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Alkermes Plc. stock. As of the latest transaction made, Morgan Stanley holds 2,569,333 shares of ALKS stock, worth $73.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,569,333

Previous 2,115,592 21.45%

Holding current value

$73.9 Million

Previous $51 Million 41.05%

% of portfolio

0.01%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$23.01 - $28.55 $10.4 Million - $13 Million	453,741 Added 21.45%	2,569,333 $71.9 Million
Q2 2024 Oct 17, 2024	BUY	$23.21 - $27.24 $3.76 Million - $4.42 Million	162,145 Added 8.3%	2,115,592 $51 Million
Q2 2024 Aug 14, 2024	BUY	$23.21 - $27.24 $3.76 Million - $4.42 Million	162,145 Added 8.3%	2,115,592 $51 Million
Q1 2024 Oct 17, 2024	SELL	$26.4 - $32.56 $4.28 Million - $5.28 Million	-162,145 Reduced 7.66%	1,953,447 $52.9 Million
Q1 2024 Aug 16, 2024	SELL	$26.4 - $32.56 $14.9 Million - $18.4 Million	-565,168 Reduced 22.44%	1,953,447 $52.9 Million
Q1 2024 May 15, 2024	SELL	$26.4 - $32.56 $14.9 Million - $18.4 Million	-565,168 Reduced 22.44%	1,953,447 $52.9 Million
Q4 2023 Aug 16, 2024	BUY	$23.37 - $28.68 $9.42 Million - $11.6 Million	403,023 Added 19.05%	2,518,615 $69.9 Million
Q4 2023 Feb 13, 2024	BUY	$23.37 - $28.68 $11.8 Million - $14.5 Million	505,823 Added 25.13%	2,518,615 $69.9 Million
Q3 2023 Nov 15, 2023	BUY	$27.17 - $31.97 $24.2 Million - $28.5 Million	891,641 Added 79.53%	2,012,792 $56.4 Million
Q2 2023 Aug 14, 2023	BUY	$28.34 - $33.63 $15.5 Million - $18.4 Million	546,580 Added 95.13%	1,121,151 $35.1 Million
Q1 2023 May 15, 2023	SELL	$25.31 - $29.02 $7.02 Million - $8.05 Million	-277,262 Reduced 32.55%	574,571 $16.2 Million
Q4 2022 Feb 14, 2023	BUY	$21.94 - $26.24 $1.79 Million - $2.15 Million	81,812 Added 10.62%	851,833 $22.3 Million
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $498,542 - $722,206	22,661 Added 3.03%	770,021 $17.2 Million
Q2 2022 Oct 27, 2022	SELL	$26.4 - $30.54 $22.2 Million - $25.7 Million	-840,979 Reduced 52.95%	747,360 $22.3 Million
Q2 2022 Aug 15, 2022	SELL	$26.4 - $30.54 $22.2 Million - $25.7 Million	-840,979 Reduced 52.95%	747,360 $22.3 Million
Q1 2022 Oct 27, 2022	BUY	$23.07 - $27.99 $19.4 Million - $23.5 Million	840,979 Added 112.53%	1,588,339 $41.8 Million
Q1 2022 May 13, 2022	BUY	$23.07 - $27.99 $27.6 Million - $33.4 Million	1,194,845 Added 303.65%	1,588,339 $41.8 Million
Q4 2021 Feb 14, 2022	SELL	$21.47 - $32.08 $507,593 - $758,435	-23,642 Reduced 5.67%	393,494 $9.15 Million
Q3 2021 Nov 15, 2021	BUY	$23.37 - $32.13 $9.75 Million - $13.4 Million	417,136 New	417,136 $12.9 Million

Others Institutions Holding ALKS

# of Institutions

362

Shares Held

181M

Call Options Held

175K

Put Options Held

96.6K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.73B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account